Samsung Biologics has secured a $280 million deal to acquire GSK’s manufacturing facilities located in Rockville, Maryland. This strategic move marks the first time the Contract Development and Manufacturing Organization (CDMO) has established direct production capabilities on U.S. soil, moving beyond its massive centralized hubs in South Korea.
The newly acquired campus boasts a total capacity of 60,000 liters, equipped to manage processes ranging from clinical trials to large-scale commercial production. Samsung Biologics has committed to continuing the manufacture of existing drugs at the site while retaining a workforce of over 500 specialized employees. The company also plans further investments in technological upgrades to enhance the resilience of the biologic medicine supply chain in the region.
This expansion occurs as U.S. tariff regulations and onshoring requirements place increasing pressure on foreign pharmaceutical entities. Owning a facility in Maryland serves as both a strategic bridge to U.S. clients and a practical solution to navigate emerging trade barriers. The transaction is expected to be finalized by the end of the first quarter of 2026.